Amgen 
Welcome,         Profile    Billing    Logout  
 160 Products   813 Diseases   160 Products   1554 Trials   75234 News 


«12...145146147148149150151152153154155...858859»
  • ||||||||||  MACH-EGFR: Individual patient data (IPD) meta-analysis of anti-EGFR monoclonal antibodies (Ab) in patients (pts) with locally advanced (LA) squamous cell carcinomas of head and neck (SCCHN) (Burgos Auditorium - Hall 3) -  Jul 27, 2023 - Abstract #ESMO2023ESMO_1321;    
    60 years 1243 (40%) 1336 (44%) ECOG PS 0 1861 (60%) 2181 (72%) 1 1185 (38%) 847 (28%) 2 33 (1%) 4 (<1%) Location Larynx 691 (22%) 219 (7%) Hypopharynx 437 (14%) 295 (10%) Oral cavity 89 (3%) 185 (6%) Oropharynx 1875 (61%) 2329 (77%) p16 positive/negative/UK 631/413/831 1784/100/445 Stage (AJCC 7) I-II 67 (2%) 15 (<1%) III 552 (18%) 383 (13%) IV 2476 (80%) 2634 (87%) Median follow-up (years) 4.0 3.9 Number of deaths (% of pts) 1209 (39%) 798 (26%) Conclusions There was no survival benefit with the addition of Ab to LRT for either comparison. Importantly, replacing CT with anti-EGFR Ab, as systemic treatment added to LRT, results in inferior survival.
  • ||||||||||  Preclinical, Journal:  Efficacy of combined targeted therapy with PI3K and CDK4/6 or PARP and WEE1 inhibitors in neuroblastoma cell lines. (Pubmed Central) -  Jul 25, 2023   
    Moreover, combining MK?1775 and BMN673 decreased the numbers of cells in S phase to a greater extent than either drug alone, while when combining PD?0332991 and BYL719 the observed effect was close to that of PD?0332991 alone. To summarize, PI3K and CDK4/6 or PARP and WEE1 exhibited synergistic anti?NB effects and lower doses of the inhibitors could be utilized, thereby potentially reducing adverse side effects.
  • ||||||||||  Imlygic (talimogene laherparepvec) / Amgen, tasadenoturev (DNX-2401) / DNAtrix
    Review, Journal, Oncolytic virus:  Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy. (Pubmed Central) -  Jul 25, 2023   
    To summarize, PI3K and CDK4/6 or PARP and WEE1 exhibited synergistic anti?NB effects and lower doses of the inhibitors could be utilized, thereby potentially reducing adverse side effects. OVs, which are advancing into clinical trials, are being envisioned as the frontier clinical anti-tumor agents coming soon.
  • ||||||||||  Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
    Review, Journal:  Sclerostin and Cardiovascular Disease. (Pubmed Central) -  Jul 25, 2023   
    One study also suggested that sclerostin lowering increases coronary artery calcification. Triangulation of evidence from different sources provides some suggestion that sclerostin lowering increases MI risk, supporting the need for CVD risk assessment when considering treatment with romosozumab.
  • ||||||||||  Lumakras (sotorasib) / Amgen
    SHERLOCK: Phase II Trial of Upfront Sotorasib with Chemotherapy and Bevacizumab for Advanced NSCLC with KRASG12C Mutation (Exhibit Hall) -  Jul 25, 2023 - Abstract #IASLCWCLC2023IASLC_WCLC_2325;    
    SHERLOCK is a phase II, single arm, open-label, multicentre, clinical trial collaboration between the Thoracic Oncology Group of Australasia and the National Health and Medical Research Council Clinical Trials Centre, University of Sydney...A total of 52 participants will be recruited to account for dropout. The SHERLOCK trial commenced recruitment in August 2022 and the study is currently ongoing.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    DEnosumab plus PD-1 Inhibitor for MAINtenance Therapy of Advanced KRAS-Mutant NSCLC - A Prospective, Single-Arm, Phase II Study (DEMAIN) (Exhibit Hall) -  Jul 25, 2023 - Abstract #IASLCWCLC2023IASLC_WCLC_2232;    
    Further analysis of a possible temporal association between ICI use and sotorasib toxicity is needed. The combination of denosumab and PD-1 inhibitors demonstrated anti-tumor activity in the advanced KRAS-mutated NSCLC with a good safety profile, which warrants further investigation.Table 1 Treatment-Related Adverse Events in the Overall PopulationAEsn (%)Any AEs11 (55)Specific AEs-Tooth-related AEs*4 (20)Arthralgia2 (10)Fatigue1 (5)Hypothyroidism2 (10)ALT/AST elevation2 (10)Creatinine elevation2 (10)Serious AEs0Deaths due to AEs0AEs leading to discontinuation1 (5)
  • ||||||||||  Leveraging NLP to Identify Biomarker-Eligible Patients (Exhibit Hall) -  Jul 25, 2023 - Abstract #IASLCWCLC2023IASLC_WCLC_2053;    
    These results were obtained from NLP analysis of attending physician notes and did not require manual searching for copies of actual genomic reports. This approach can potentially expedite identification of non-small cell lung cancer patients for complex clinical trials.
  • ||||||||||  elesclomol (STA-4783) / Madrigal Pharma
    Targeting ATP7A by Elesclomol-Copper Derived Endoplasmic Reticulum Stress to Mediate Cuproptosis in KRAS-G12 Mutant LUAD (Exhibit Hall) -  Jul 25, 2023 - Abstract #IASLCWCLC2023IASLC_WCLC_1946;    
    Elesclomol transports exogenous copper ions into LUAD cells, activates endoplasmic reticulum stress by inducing the accumulation of misfolded proteins, and upregulates the expression of E3 ligase RNF207, which induces ubiquitination and degradation of ATP7A and further increases the retention of copper ions in cells, ultimately mediating cuproptosis of KRASG12 mutant LUAD cells. In summary, targeting copper metabolism may break through the bottleneck of KRASG12 mutant LUAD treatment.
  • ||||||||||  Ameile (aumolertinib) / Jiangsu Hansoh Pharma, EQRx
    A Case of Long PFS by Aumolertinib in Advanced Lung Cancer with Multiple Metastases lncluding Brain Metastasis (Exhibit Hall) -  Jul 25, 2023 - Abstract #IASLCWCLC2023IASLC_WCLC_1714;    
    In our case, aumolertinib monotherapy brought more surprises for advanced lung adenocarcinoma patients with multiple metastases in addition to brain metastasis,which could take into account both efficacy and safety. The rapid effect brought by EGFR-TKI can delay the timing of local treatment for brain and bone metastases, thereby enabling patients to have a higher quality of life.
  • ||||||||||  Krazati (adagrasib) / Mirati, ARS-1620 / Kura Oncology, J&J, Araxes Pharma, Lumakras (sotorasib) / Amgen
    Synergism of KRAS G12C Inhibitor and mTOR Inhibitor in Lung Adenocarcinoma and Squamous Cell Carcinoma (Exhibit Hall) -  Jul 25, 2023 - Abstract #IASLCWCLC2023IASLC_WCLC_1213;    
    Combination of KRAS G12C inhibitor (AMG-510, MRTX849, and ARS-1620) and mTOR inhibitor (Everolimus) showed synergism in both adenocarcinoma and squamous cell carcinoma cell lines. The targetable somatic variant G12C in KARS should be explored in squamous cell carcinoma as well as in adenocarcinoma.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Osteoporotic Vertebral Fractures in Non-small Cell Lung Cancer : A Cracking Connection (Exhibit Hall) -  Jul 25, 2023 - Abstract #IASLCWCLC2023IASLC_WCLC_1194;    
    Diagnosis and management of OVF in this setting requires a multidisciplinary approach. Identifying risk factors such as corticosteroid exposure and malnutrition should be part of a comprehensive prevention policy to mitigate osteoporosis complications.
  • ||||||||||  Tagrisso (osimertinib) / AstraZeneca
    A Novel Anti-EGFR/CD3 Bispecific Antibody Exhibits Potent Efficacy for Osimertinib-resistant NSCLC (405B) -  Jul 25, 2023 - Abstract #IASLCWCLC2023IASLC_WCLC_989;    
    Additionally, the total protein of H1975-OR treated with BC3448 or Panitumumab for 2 days was subsequently subjected for Sally Sue Simple Western analysis. BC3448 exhibited potent antitumor effect in vitro and in vivo and might be a BC3448 exhibited potent antitumor effect in vitro and in vivo and might be a promising agent for Osimertinib-resistant NSCLC.
  • ||||||||||  SB202190 / Amgen
    Journal:  Photobiomodulation inhibits the expression of chondroitin sulfate proteoglycans after spinal cord injury via the Sox9 pathway. (Pubmed Central) -  Jul 25, 2023   
    Furthermore, we found that the increased levels of p-Smad3, p-P38 and p-Erk in inflammatory astrocytes were reduced after photobiomodulation treatment and after delivery of inhibitors including FR 180204, (E)-SIS3, and SB 202190...In summary, our findings show that photobiomodulation modulates the expression of chondroitin sulfate proteoglycans, and versican is one of the key target molecules of photobiomodulation. MAPK/Sox9 and Smad3/Sox9 pathways may play a role in the effects of photobiomodulation on chondroitin sulfate proteoglycan accumulation after spinal cord injury.
  • ||||||||||  Praluent (alirocumab) / Sanofi, Regeneron, Repatha (evolocumab) / Amgen, Astellas
    Retrospective data, Review, Journal:  Application Value of PCSK9 Inhibitor in Cardiovascular High Risk Patients: A Meta-Analysis. (Pubmed Central) -  Jul 24, 2023   
    In terms of effectiveness, PCSK9 inhibitors reduced the risk of major adverse cardiovascular events(MACE) (OR=0.89, 95% Cl: 0.83-0.95, P=0.0009), but did not significantly reduce the risk of cardiovascular death (OR=0.95, 95% Cl: 0.84-1.07, P=0.38) or all-cause death (OR=0.93, 95% Cl: 0.85-1.03, P=0.18); In terms of safety, PCSK9 did not increase the risk of treatment-emergent adverse events (TEAE)(OR=0.98, 95% Cl: 0.94-1.02, P=0.28). PCSK9 inhibitors can significantly reduce the risk of MACE in patients with high cardiovascular risk, which is well tolerated, but the impact on the risk of death is unclear.